Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2000 Aug;24(8):671-80.
doi: 10.1016/s0145-2126(00)00037-0.

Poor Prognosis Acute Myelogenous Leukemia: 1 - Response to Treatment With High Dose Cytarabine/Mitoxantrone/Ethyol @ (Amifostine)

Affiliations
Clinical Trial

Poor Prognosis Acute Myelogenous Leukemia: 1 - Response to Treatment With High Dose Cytarabine/Mitoxantrone/Ethyol @ (Amifostine)

H D Preisler et al. Leuk Res. .

Abstract

Twenty patients with poor prognosis AML and four patients in the blastic phase of a myeloproliferative disorder were treated with two 'pulses' of therapy each consisting of two doses of high dose araC (separated by 12 h) followed by a single dose of mitoxantrone. The pulses were separated by 96 h. Amifostine was then administered tiw. The median age of the population was 68 years with 88% of patients having had either a prior MDS, MPD or toxic exposure. The acute leukemia of 58% of patients either entered a CR or reverted to preleukemic state. For patients under 70 years of age, treatment produced 62% CRs with a leukemia free decision marrow in 77%. For patients over 70 years the CR rate was 27% with 36% of patients having a leukemia free decision marrow.

Similar articles

See all similar articles

Publication types

MeSH terms

Feedback